do you regain weight after stopping semaglutide What Happens Semaglutide? People Who Stop Taking Weight-Loss

doi: 10.3389/fmed.2022.875430 Summary Keywords glucagon-like peptide-1 receptor agonist (GLP-1RA), incretin based therapy, glucose-depent insulinotropic peptide (GIP), dual agonists, tirzepatide, type 2 diabetes Citation Gallwitz B (2022) Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity

A Survey and Guide to the Development of Fatty Acid-derivatized Peptide Therapeutics

The article cites a recent interview with Sandoz CEO, Richard Saynor, who claims that Novo Nordisk never filed a patent for Ozempic, the blockbuster weight-loss drug, in Canada

Journal of Biomedical Nanotechnology